Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PSY004
MIFTS: 67

Psychotic Disorder

Categories: Mental diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Psychotic Disorder

About this section

MalaCards integrated aliases for Psychotic Disorder:

Name: Psychotic Disorder 12 15
Psychotic Disorders 42 15 71
Mental or Behavioural Disorder 12 17
Mental Disorders 71
Psychotic 54

Classifications:

MalaCards categories:
Anatomical: Mental diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32


Sources

Summaries for Psychotic Disorder

About this section
MedlinePlus : 42 Psychotic disorders are severe mental disorders that cause abnormal thinking and perceptions. People with psychoses lose touch with reality. Two of the main symptoms are delusions and hallucinations. Delusions are false beliefs, such as thinking that someone is plotting against you or that the TV is sending you secret messages. Hallucinations are false perceptions, such as hearing, seeing, or feeling something that is not there. Schizophrenia is one type of psychotic disorder. People with bipolar disorder may also have psychotic symptoms. Other problems that can cause psychosis include alcohol and some drugs, brain tumors, brain infections, and stroke. Treatment depends on the cause of the psychosis. It might involve drugs to control symptoms and talk therapy. Hospitalization is an option for serious cases where a person might be dangerous to himself or others.

MalaCards based summary : Psychotic Disorder, also known as psychotic disorders, is related to schizophreniform disorder and schizophrenia 18, and has symptoms including photophobia, lethargy and restlessness. An important gene associated with Psychotic Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are Beta-Adrenergic Signaling and Circadian entrainment. The drugs Reboxetine and Etomidate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A cognitive disorder that involves abnormal thinking and perceptions resulting in a disconnection with reality.

Wikipedia : 74 Psychosis is an abnormal condition of the mind that results in difficulties determining what is real and... more...

Sources

Related Diseases for Psychotic Disorder

About this section

Diseases related to Psychotic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 672)
# Related Disease Score Top Affiliating Genes
1 schizophreniform disorder 34.0 PRODH PRL NRG1 HTR2A DTNBP1 DRD4
2 schizophrenia 18 33.3 SLC1A1 PRODH NRXN1
3 delusional disorder 33.3 PRL HTR2A DRD4 DRD3 DRD2 DRD1
4 schizophrenia 33.2 SYN2 SLC6A4 SLC1A1 RGS4 PRODH PRL
5 schizoaffective disorder 33.2 SLC6A4 SLC1A1 RGS4 PRODH PRL NRXN1
6 drug psychosis 33.0 HTR2A DRD4 DRD3 DRD2 DRD1 COMT
7 phenylketonuria 32.8 PRODH MAOB DRD2
8 schizophrenia 9 32.6 PRODH DISC1
9 schizophrenia 4 32.2 SLC1A1 PRODH
10 bipolar disorder 31.9 SYN2 SLC6A4 SLC1A1 RGS4 PRODH PRL
11 depression 31.8 SLC6A4 HTR2A BDNF
12 substance abuse 31.7 SLC6A4 PRODH PRL HTR2A DRD4 DRD3
13 mood disorder 31.7 SLC6A4 PRODH NRG1 MAOB HTR2A DRD4
14 personality disorder 31.7 SLC6A4 PRL MAOB HTR2A DRD4 DRD3
15 alcohol use disorder 31.6 SLC6A4 HTR2A DRD3 DRD2 DRD1 COMT
16 mental depression 31.6 SLC6A4 PRODH HTR2A DRD4 DRD3 DRD2
17 anxiety 31.5 SLC6A4 SLC1A1 PRODH PRL MAOB HTR2A
18 substance-induced psychosis 31.5 PRODH HTR2A DTNBP1 DRD4 DRD3 DRD2
19 alzheimer disease 31.4 SLC6A4 NRG1 MAOB HTR2A DRD4 DRD3
20 tardive dyskinesia 31.4 HTR2A DRD3 DRD2 COMT
21 major depressive disorder 31.4 SLC6A4 PRL MAOB HTR2A DTNBP1 DRD4
22 generalized anxiety disorder 31.3 SLC6A4 PRODH HTR2A DRD2 COMT BDNF
23 post-traumatic stress disorder 31.3 SLC6A4 NRG1 MAOB HTR2A DRD2 COMT
24 bipolar i disorder 31.3 SLC6A4 NRG1 HTR2A DTNBP1 DRD4 DRD3
25 traumatic brain injury 31.3 DRD2 COMT BDNF
26 brain injury 31.3 DRD2 COMT BDNF
27 eating disorder 31.3 SLC6A4 HTR2A DRD3 DRD2 COMT BDNF
28 cannabis abuse 31.3 NRG1 DRD4 DRD2 COMT BDNF
29 obsessive-compulsive disorder 31.3 SLC6A4 SLC1A1 PRL MAOB HTR2A DRD4
30 paranoid schizophrenia 31.3 SLC6A4 PRL NRXN1 HTR2A DISC1 COMT
31 endogenous depression 31.3 SLC6A4 PRL HTR2A COMT BDNF
32 schizotypal personality disorder 31.2 PRODH NRG1 DTNBP1 DRD4 DRD2 DISC1
33 alcohol dependence 31.2 SLC6A4 PRL MAOB HTR2A DRD4 DRD3
34 constipation 31.1 SLC6A4 NRXN1 HTR2A BDNF
35 body dysmorphic disorder 31.1 SLC6A4 SLC1A1 HTR2A
36 borderline personality disorder 31.1 SLC6A4 PRL HTR2A DRD2 COMT BDNF
37 neuroleptic malignant syndrome 31.1 HTR2A DRD3 DRD2 DRD1
38 cannabis dependence 31.1 NRG1 DRD2 COMT
39 hyperprolactinemia 31.0 PRL HTR2A DRD4 DRD2
40 dystonia 31.0 PRL MAOB HTR2A DRD3 DRD2 DRD1
41 drug dependence 31.0 SLC6A4 DRD3 DRD2 DRD1 BDNF
42 galactorrhea 31.0 PRL DRD2
43 neurotic disorder 31.0 SLC6A4 HTR2A BDNF
44 autism spectrum disorder 31.0 SLC6A4 SLC1A1 PRODH NRXN1 NRG1 MAOB
45 sleep disorder 31.0 SLC6A4 PRL HTR2A DRD2 BDNF
46 panic disorder 31.0 SLC6A4 PRL HTR2A DRD4 DRD3 DRD2
47 sexual disorder 31.0 SLC6A4 PRL HTR2A DRD4 DRD3 DRD2
48 antisocial personality disorder 31.0 SLC6A4 PRL MAOB HTR2A DRD4 DRD2
49 tic disorder 30.9 SLC6A4 SLC1A1 PRODH NRXN1 HTR2A DRD4
50 migraine with or without aura 1 30.9 SLC6A4 PRL MAOB HTR2A DRD4 DRD3

Graphical network of the top 20 diseases related to Psychotic Disorder:



Diseases related to Psychotic Disorder
Sources

Symptoms & Phenotypes for Psychotic Disorder

About this section

UMLS symptoms related to Psychotic Disorder:


photophobia, lethargy, restlessness, personality changes, agitation, pseudobulbar behavioral symptoms, sleep disturbances, mental and behavioral signs and symptoms, forgetful, decrease in appetite, symptoms, nervousness, feeling jittery, alexithymia, increased libido, numbness, psychiatric symptom, hallucinations, auditory, hallucinations, visual, numbness localized, feeling detached, feeling strange, feeling weightless, floating feeling, dejection emotional, depressed reaction, hallucinations, sensory, restless sleep, difficulty sleeping, excitability, depression aggravated, agitation mental, numb mouth, opiate withdrawal symptoms, clouded consciousness, trembling inside, sluggishness, catatonic reaction

GenomeRNAi Phenotypes related to Psychotic Disorder according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.73 COMT
2 Decreased viability GR00249-S 9.73 COMT DTNBP1 MAOB PRODH SLC6A4
3 Decreased viability GR00381-A-1 9.73 PRODH SLC6A4
4 Decreased viability GR00381-A-3 9.73 SLC6A4
5 Decreased viability GR00386-A-1 9.73 COMT DAOA DRD1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.58 DRD4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.58 PRODH
8 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.58 DRD4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.58 PRODH
10 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.58 DRD3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.58 DRD4
12 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.58 PRODH
13 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.58 PRODH
14 Increased shRNA abundance (Z-score > 2) GR00366-A-33 9.58 PRODH
15 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.58 DRD3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.58 DRD4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-58 9.58 DRD3 DRD4 PRODH
18 Increased shRNA abundance (Z-score > 2) GR00366-A-66 9.58 PRODH
19 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.58 PRODH
20 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.58 PRODH
21 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.58 PRODH

MGI Mouse Phenotypes related to Psychotic Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 BDNF COMT DAO DISC1 DRD1 DRD2
2 homeostasis/metabolism MP:0005376 10.06 BDNF COMT DAO DISC1 DRD1 DRD2
3 nervous system MP:0003631 9.89 BDNF COMT DAO DISC1 DRD1 DRD2
4 digestive/alimentary MP:0005381 9.8 BDNF DRD1 DRD2 DRD3 HTR2A NRXN1
5 renal/urinary system MP:0005367 9.17 COMT DRD2 DRD3 DTNBP1 MAOB RGS4
Sources

Drugs & Therapeutics for Psychotic Disorder

About this section

Drugs for Psychotic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 612)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
2
Etomidate Approved Phase 4 33125-97-2 36339 667484
3
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
4
Amlodipine Approved Phase 4 88150-42-9 2162
5
Atenolol Approved Phase 4 29122-68-7 2249
6
Cinnarizine Approved, Investigational Phase 4 298-57-7 1547484 2761
7
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
8
Asenapine Approved Phase 4 65576-45-6, 85650-56-2 3001386
9
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
10
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
11
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
12
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
13
Pimozide Approved Phase 4 2062-78-4 16362
14
Perphenazine Approved Phase 4 58-39-9 4748
15
Trifluoperazine Approved, Investigational Phase 4 117-89-5 5566
16
leucovorin Approved Phase 4 58-05-9 6006 143
17
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
18
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
19
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
20 Perazine Approved, Investigational Phase 4 84-97-9
21
Benperidol Approved, Investigational Phase 4 2062-84-2
22 bromperidol Approved, Investigational Phase 4 10457-90-6 2448
23
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
24
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
25
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
26
Molindone Approved Phase 4 7416-34-4 23897
27
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
28
Allopurinol Approved Phase 4 315-30-0 2094
29
Pravastatin Approved Phase 4 81093-37-0 54687
30
Zinc Approved, Investigational Phase 4 7440-66-6 32051
31
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
32
Ondansetron Approved Phase 4 99614-02-5 4595
33
Pramlintide Approved, Investigational Phase 4 151126-32-8
34
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
35
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
36
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
37
Ferrous succinate Approved Phase 4 10030-90-7
38
Cyproheptadine Approved Phase 4 129-03-3 2913
39
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
40
Zolpidem Approved Phase 4 82626-48-0 5732
41
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
42
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
43
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
44
Megestrol acetate Approved, Investigational, Vet_approved Phase 4 595-33-5 11683
45
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
46
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
47
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
48
Nortriptyline Approved Phase 4 72-69-5 4543
49
Gliclazide Approved Phase 4 21187-98-4 3475
50
Insulin glargine Approved Phase 4 160337-95-1

Interventional clinical trials:

(show top 50) (show all 3189)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications Unknown status NCT02213887 Phase 4 Pantoprazole;Pantoprazole
2 An Open-label Switch Study to Asenapine in the Early Stage of Psychosis Unknown status NCT01968161 Phase 4 Asenapine
3 A Pilot Study to Determine How Frequency of Administration Modifies Steady-State Plasma Concentrations of Orally Administered Clozapine Unknown status NCT02286206 Phase 4 Clozapine
4 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis- An Investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole Versus Quetiapine in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
5 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
6 Determining the Efficacy and Tolerance of Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
7 Identifying Predictors of Response in 12 Weeks of Treatment With Antipsychotics Using a Treatment Algorithm for Schizophrenia Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
8 A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
9 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
10 A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Unknown status NCT02935998 Phase 4 Ziprasidone
11 A Study on the Efficacy, Pharmacokinetics and Adverse Effects of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
12 Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
13 Effectiveness of Long-Acting Risperidone in the Maintenance Treatment of First-Episode Schizophrenia Unknown status NCT00220714 Phase 4 atypical antipsychotics:oral vs. long-acting route
14 Association of the Amisulpride Treatment Response in Patients With Schizophrenia With the Findings of Brain Structural Magnetic Resonance Imaging Unknown status NCT02095938 Phase 4 amisulpride
15 Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
16 Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic REM Sleep Behavior Disorder: a Pilot Study Unknown status NCT02836743 Phase 4 Circadin;Placebo
17 Identification and Treatment of the Liability to Develop Schizophrenia Unknown status NCT00305474 Phase 4 Risperidone
18 Phase IV Study of Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
19 Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder Unknown status NCT02252341 Phase 4
20 A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
21 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
22 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
23 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial. Unknown status NCT00437099 Phase 4 Omacor®;Placebo
24 Omega-3 Fatty Acids in First-episode Schizophrenia - a Randomized Controlled Study of Efficacy and Relapse Prevention (OFFER). Rationale, Design, and Methods. Unknown status NCT02210962 Phase 4
25 The Effect of a Community-based Long-acting Antipsychotic-treated Management Model on the Violence Risk of Patients With Schizophrenia: a 1-year, Open-label Randomized Controlled Study Unknown status NCT03080194 Phase 4 paliperidone palmitate;control group
26 Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy ---a Randomized Control Double-Blind Clinical Trial Unknown status NCT02305394 Phase 4 ketamine and propofol;propofol and normal saline
27 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
28 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
29 Are Antipsychotics Neurotoxic or Neuroprotective? A Long-term Comparison of Two Treatment Strategies Unknown status NCT02435095 Phase 4 Maintenance treatment;Intermittent treatment
30 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4 Quetiapine fumarate;Haloperidol
31 Delirium: Is Prophylactic Drug Therapy Useful in High Risk Patients as Defined by the Delirium Risk Prediction Model? Unknown status NCT03199950 Phase 4 Haloperidol;Placebo Oral Tablet
32 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
33 Frailty and Cognitive Function Assessment of TAVI Patients (The Hungarian Frailty Score) - Observational, Prospective, Singe Center Study Unknown status NCT02650388 Phase 4
34 A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Aptensio XR® in Children Ages 4 to Under 6 Years Diagnosed With Attention Deficit-Hyperactivity Disorder (ADHD) Unknown status NCT02683265 Phase 4 Aptensio XR;Placebo
35 Melatonin Use in the Intensive Care Elderly Population Unknown status NCT03013790 Phase 4 Melatonin
36 A Pilot Open Trial Of Ziprasidone, Early In The Course Of Pediatric Psychotic Illness Completed NCT00199940 Phase 4 Ziprasidone
37 An Open-labeled, Parallel-group, Single-blinded (Rater) Pilot Study to Investigate the Neuroprotective Effects of of Low-dose Lithium in Young Subjects at Ultra High Risk (UHR) of Developing a First-episode Psychotic Disorder Completed NCT00202306 Phase 4 lithium carbonate
38 Therapeutic Effect Between Quetiapine and Haloperidol on the Treatment of Methamphetamine - Induced Psychosis Completed NCT01939093 Phase 4 Diazepam;Stugeron
39 Efficacy and Safety of Paliperidone ER in Patients With First Episode Psychosis: an Open-label, Prospective Multi-center Study Completed NCT01157585 Phase 4 paliperidone ER
40 Efficacy and Safety With Ziprasidone in the Treatment of First-episode Schizophrenia Spectrum Disorder: Multi-center Study Completed NCT01157559 Phase 4 Ziprasidone
41 Efficacy and Safety of Aripiprazole in Patients With First Episode Psychosis: an Open-label, Prospective Multi-center Study Completed NCT01026584 Phase 4 Aripiprazole
42 The Cognitive Effects of Risperidone and Olanzapine Completed NCT00108368 Phase 4 Risperidone;Olanzapine
43 Treatment of Major Depressive Episodes During the Course of Psychotic Disorders With Duloxetine Completed NCT00224302 Phase 4 Duloxetine
44 An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease Completed NCT00095810 Phase 4 aripiprazole
45 A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT00137020 Phase 4 ziprasidone
46 Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI): A Pilot Study Completed NCT00453804 Phase 4 injectable naltrexone;oral naltrexone
47 Childhood Onset Psychotic Disorders: Characterization and Treatment With Atypical Neuroleptics Completed NCT00001656 Phase 4 Olanzapine;Clozapine
48 An Open, Multicenter, Non-Comparative Study To Assess The Efficacy And Tolerability Of Intramuscular Ziprasidone Followed By Oral Ziprasidone In Patients With Acute Psychosis Completed NCT00644800 Phase 4 Ziprasidone
49 Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis: A Randomised, Double Blind, Placebo-Controlled Treatment Trial Completed NCT00396643 Phase 4 Omega 3 fatty acids
50 Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol IM Injection for Treatment of Acute Psychotic Agitation in Schizophrenia Completed NCT00859872 Phase 4 risperidone oral solution;haloperidol

Search NIH Clinical Center for Psychotic Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


acetophenazine
Acetophenazine maleate
Carbamazepine
Chlorpromazine
Chlorpromazine hydrochloride
Chlorprothixene
Clozapine
CLOZAPINE (CARACO)
CLOZAPINE (CLOZARIL)
CLOZAPINE (IVAX)
CLOZAPINE (TEVA)
CLOZAPINE (VERSACLOZ)
Droperidol
Fazaclo
Fluphenazine
fluphenazine decanoate
Fluphenazine enanthate
Fluphenazine Hydrochloride
Haloperidol
haloperidol decanoate
Haloperidol lactate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Lorazepam
Loxapine
Loxapine hydrochloride
Loxapine Succinate
Mesoridazine
Mesoridazine besylate
Molindone
Molindone Hydrochloride
Mylan brand of clozapine
olanzapine
Perphenazine
Pimozide
Prochlorperazine
Prochlorperazine Edisylate Salt
Prochlorperazine Maleate
Promazine
Promazine Hydrochloride
quetiapine
Quetiapine fumarate
Thioridazine
Thioridazine Hydrochloride
Thiothixene
Thiothixene hydrochloride
Trifluoperazine
Trifluoperazine hydrochloride
Triflupromazine
Triflupromazine hydrochloride
UDL brand of clozapine
Sources

Genetic Tests for Psychotic Disorder

About this section
Sources

Anatomical Context for Psychotic Disorder

About this section

MalaCards organs/tissues related to Psychotic Disorder:

40
Brain, Testes, Cortex, Eye, Prefrontal Cortex, Heart, Pituitary
Sources

Publications for Psychotic Disorder

About this section

Articles related to Psychotic Disorder:

(show top 50) (show all 8759)
# Title Authors PMID Year
1
Advances in clinical staging, early intervention, and the prevention of psychosis. 61 42
32047596 2019
2
Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. 42
32197092 2020
3
On the Origins of Schizophrenia. 42
32233682 2020
4
Alterations of the dopamine transporter in resting lymphocytes of patients with different psychotic disorders. 61 54
19910055 2010
5
Neuregulin 1-stimulated phosphorylation of AKT in psychotic disorders and its relationship with neurocognitive functions. 61 54
19524002 2009
6
Discontinued psychiatric drugs in 2008. 54 61
19715445 2009
7
Discovery and biological profile of isoindolinone derivatives as novel metabotropic glutamate receptor 1 antagonists: a potential treatment for psychotic disorders. 54 61
19692242 2009
8
Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole. 61 54
19644230 2009
9
Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. 61 54
18562404 2009
10
McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. 61 54
19200422 2009
11
Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features. 61 54
19268543 2009
12
Association of a nonsynonymous variant of DAOA with visuospatial ability in a bipolar family sample. 61 54
18466879 2008
13
5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. 61 54
18047755 2008
14
Investigation of serum BDNF levels in drug-naive patients with schizophrenia. 61 54
18502013 2008
15
Catechol-O-methyltransferase Val158Met polymorphism and clinical characteristics in first episode non-affective psychosis. 54 61
18092319 2008
16
The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. 54 61
17555717 2008
17
A dysbindin risk haplotype associated with less severe manic-type symptoms in psychosis. 61 54
18162312 2008
18
Association analysis of exon III and exon I polymorphisms of the dopamine D4 receptor locus in Mexican psychotic patients. 61 54
17822780 2007
19
D-amino acid oxidase (DAO) genotype and mood symptomatology in schizophrenia. 61 54
17890006 2007
20
Association of distinct allelic haplotypes of DISC1 with psychotic and bipolar spectrum disorders and with underlying cognitive impairments. 54 61
17673452 2007
21
An association study between cathechol-O-methyltransferase gene and mental retardation in the Chinese Han population. 61 54
17442488 2007
22
Association between the DTNBP1 gene and intelligence: a case-control study in young patients with schizophrenia and related disorders and unaffected siblings. 54 61
17445278 2007
23
Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. 54 61
17403981 2007
24
Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. 61 54
17355517 2007
25
The child and adolescent first-episode psychosis study (CAFEPS): design and baseline results. 54 61
17267179 2007
26
Diagnostic stability over 3 years in a total group of first-episode psychosis patients. 54 61
17523030 2007
27
Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications. 61 54
16793187 2006
28
Risk factors for completed suicide in schizophrenia and other chronic psychotic disorders: a case-control study. 61 54
16626940 2006
29
Common alterations in the serotonin transporter in platelets and lymphocytes of psychotic patients. 61 54
16453253 2006
30
Sensory gating deficits, pattern completion, and disturbed fronto-limbic balance, a model for description of hallucinations and delusions in schizophrenia. 61 54
16824690 2006
31
COMT genetic variation confers risk for psychotic and affective disorders: a case control study. 61 54
16232322 2005
32
Hyperprolinemia is a risk factor for schizoaffective disorder. 61 54
15494707 2005
33
Linkage disequlibrium in the DTNBP1 (dysbindin) gene region and on chromosome 1p36 among psychotic patients from a genetic isolate in Israel: findings from identity by descent haplotype sharing analysis. 54 61
15211634 2004
34
Clinical features of psychotic disorders and polymorphisms in HT2A, DRD2, DRD4, SLC6A3 (DAT1), and BDNF: a family based association study. 61 54
14755448 2004
35
Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. 54 61
15539862 2004
36
GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis. 61 54
12811640 2003
37
Premorbid functioning in early-onset psychotic disorders. 61 54
12921474 2003
38
[A case report of factitious disorder with hallucinations]. 54 61
14569475 2003
39
The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. 54 61
11910268 2002
40
Tryptophan hydroxylase gene and major psychoses. 54 61
11472792 2001
41
Children and adolescents with psychotic disorder not otherwise specified: a 2- to 8-year follow-up study. 61 54
11458307 2001
42
DRD4 exon 3 variants associated with delusional symptomatology in major psychoses: a study on 2,011 affected subjects. 54 61
11353451 2001
43
Dopamine D4 receptor (DRD4) gene polymorphism in the first psychotic episode. 61 54
11282178 2001
44
New neurochemical markers for psychosis: a working hypothesis of their operation. 61 54
11059795 2000
45
Clinical predictors of acute response with quetiapine in psychotic mood disorders. 54 61
10817103 2000
46
Clozapine treatment in a population of adults with mental retardation. 61 54
10695641 2000
47
Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants. 54 61
10208638 1999
48
Elevated prolactin in pediatric patients on typical and atypical antipsychotics. 54 61
10630453 1999
49
5-Hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: suppression by mu-opiate receptor activation. 54 61
9881863 1998
50
Twelve-nucleotide repeat polymorphism of D4 dopamine receptor gene in Chinese familial schizophrenic patients. 61 54
9532348 1998
Sources

Variations for Psychotic Disorder

About this section